Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, highlights some of the challenges associated with the use of commercial CAR-T therapies in multiple myeloma, outlining potential strategies to overcome these obstacles. Dr Lin explains that access to CAR-T therapy is greatly limited by manufacturing time and limited resources. It is therefore necessary to select patients who are most likely to have good outcomes with CAR-T therapy. Several CAR-T platforms with shorter manufacturing time as well as allogeneic CAR-Ts are currently being developed to improve access to these novel therapies. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.